Figure 2 | British Journal of Cancer

Figure 2

From: Changes in circulating microRNA-126 during treatment with chemotherapy and bevacizumab predicts treatment response in patients with metastatic colorectal cancer

Figure 2

Mean cir-miRNA-126 (cir-miRNA-126) levels according to treatment response (PD, SD, PR, and CR). Horizontal lines mark the respective standard deviation intervals. The broken time line between first clinical evaluation (after 3 weeks) and progression indicates that this time period varies between the patients. As it appears from the overlapping s.d. intervals there were no significant differences between the means of the respective response groups at baseline and first evaluation. The mean cir-miRNA-126 of the PD group was significantly higher than that of the remaining three response groups (P<0.05) at progression. (PD, N=4), (SD, N=28), (PR, N=29), and (CR=2).

Back to article page